Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2005 Aug;89(8):999-1003.
doi: 10.1136/bjo.2004.062596.

Dosage dependency of intravitreal triamcinolone acetonide as treatment for diabetic macular oedema

U H M Spandau  1 , M Derse, P Schmitz-Valckenberg, C Papoulis, J B Jonas
Affiliations
Clinical Trial

Dosage dependency of intravitreal triamcinolone acetonide as treatment for diabetic macular oedema

U H M Spandau et al. Br J Ophthalmol. 2005 Aug.

Abstract

Aim: To evaluate the effect of different doses of intravitreal triamcinolone acetonide on diffuse diabetic macular oedema.

Methods: The prospective, randomised, double masked, clinical interventional study included 27 eyes (27 patients) with diffuse diabetic macular oedema. They were randomly divided into three study groups receiving an intravitreal injection of filtered triamcinolone acetonide of about 2 mg (n = 8 eyes), 5 mg (n = 10), or 13 mg (n = 9), respectively. Dosage measurement was performed before filtration. Mean follow up was 6.6 (SD 2.4) months (3-12 months). Main outcome measures were visual acuity and intraocular pressure.

Results: Maximal increase in visual acuity was significantly (p = 0.046; 95% CI: 0.032 to 2.99; r = 0.38) correlated with the dosage of intravitreal triamcinolone acetonide. Additionally, the duration of the effect of intravitreal triamcinolone acetonide increased significantly with the dosage of intravitreal triamcinolone acetonide (r = 0.45; p = 0.014). Increase in intraocular pressure during follow up was statistically not significantly associated with the dosage used (p = 0.77).

Conclusions: In patients with diffuse diabetic macular oedema receiving intravitreal triamcinolone acetonide, treatment response may last longer and be more pronounced with a dosage of 13 mg than in lower doses of 5 mg or 2 mg. Triamcinolone acetonide induced increase in intraocular pressure may not be markedly associated with the dosage used.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Scatter plot showing the correlation between the dosage of intravitreally injected triamcinolone acetonide and maximal gain in visual acuity during follow up (p = 0.046; 95% CI: 0.032 to 2.99; correlation coefficient r = 0.38; equation of the regression line: (maximal gain in visual acuity)  =  1.51 + (dosage study group number) −0.60.
Figure 2
Figure 2
Scatter plot showing the correlation between the dosage of intravitreally injected triamcinolone acetonide and the duration of the effect of intravitreal triamcinolone acetonide (p = 0.014; correlation coefficient r = 0.45; 95% CI: 0.498 to 2.977; equation of the regression line: (peak time in months)  =  1.71 + (dosage study group number) −0.92.
See this image and copyright information in PMC

References

    1. Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema. ETDRS report number 1. Arch Ophthalmol 1985;103:1796–806. - PubMed
    1. Early Treatment Diabetic Retinopathy Study Research Group. Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Ophthalmology 1991;98:766–85. - PubMed
    1. McDonald HR, Schatz H. Grid photocoagulation for diffuse macular edema. Retina 1985;5:65–72. - PubMed
    1. Lee CM, Olk RJ. Modified grid laser photocoagulation for diffuse diabetic macular edema. Long-term visual results. Ophthalmology 1991;98:1594–602. - PubMed
    1. Jonas JB, Söfker A. Intraocular injection of crystalline cortisone as adjunctive treatment of diabetic macular edema. Am J Ophthalmol 2001;132:425–7. - PubMed

Publication types

MeSH terms